6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects. | Zendy

C P Quilley | Zendy; J C McGiff | Zendy; W H Lee | Zendy; F.F. Sun | Zendy; Patrick Y.-K. Wong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.

Author(s) -

C P Quilley,

J C McGiff,

W H Lee,

F.F. Sun,

Patrick Y.-K. Wong

Publication year - 1980

Publication title -

hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.986

H-Index - 265

eISSN - 1524-4563

pISSN - 0194-911X

DOI - 10.1161/01.hyp.2.4.524

Subject(s) - prostacyclin , metabolite , platelet , chemistry , potency , platelet aggregation , medicine , prostaglandin e1 , metabolism , endocrinology , biological activity , pharmacology , biochemistry , in vitro

Hepatic metabolism of prostacyclin (PGI2) results in the formation of several biologically inactive lipids and one stable product that has the same chromatographic and biological properties as authentic 6-keto PGE1. Both prostaglandins, 6-keto PGE1 and PGI2, have comparable potency in their antiaggregatory and disaggregatory effects on platelets. They contract the superfused rat stomach strip but differ in their effects on the bovine coronary artery, which is contracted by 6-keto PGE1 but relaxed by PGI2. Further, 6-keto PGE1 is considerably more stable than PGI2. Thus, 6-keto PGE1 could account for some of the prolonged effects occasionally seen with PGI2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research